Profile data is unavailable for this security.
About the company
Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider company. The Company is engaged in manufacturing of diverse range of pharmaceutical products oral solids, oral liquids, ointment for non-oncology products range and also produces tablets, capsule/lyohilized/dry powder injections for oncology product range. It focuses on oncology therapeutics, and other generics. The Company manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The Company primarily focuses on oncology therapeutics. It is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, and Pazopanib.
- Revenue in INR (TTM)1.71bn
- Net income in INR126.93m
- Incorporated1993
- Employees388.00
- LocationMedicamen Biotech Ltd1506, Chiranjiv Tower, 43, Nehru PlaceNEW DELHI 110019IndiaIND
- Phone+91 1 147589500
- Fax+91 1 126213081
- Websitehttps://medicamen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medico Remedies Ltd | 1.32bn | 69.58m | 4.02bn | -- | 58.13 | -- | 40.88 | 3.05 | 0.8326 | 0.8326 | 15.75 | -- | -- | -- | -- | -- | -- | 4.76 | -- | 10.00 | 24.15 | 24.40 | 5.29 | 3.14 | -- | 11.07 | -- | -- | 16.04 | 18.14 | 48.09 | 42.78 | 52.68 | -- |
| Lyka Labs Ltd | 1.06bn | -35.60m | 4.16bn | 713.00 | -- | -- | 42.29 | 3.94 | -1.23 | -1.23 | 33.69 | -- | -- | -- | -- | -- | -- | -5.48 | -- | -9.31 | 61.37 | 59.75 | -3.34 | -10.63 | -- | 0.5422 | -- | -- | -52.05 | 8.95 | -133.88 | -- | 17.78 | -- |
| Venus Remedies Ltd. | 5.62bn | 290.26m | 4.38bn | 998.00 | 15.07 | -- | 7.57 | 0.7788 | 21.73 | 21.73 | 420.31 | -- | -- | -- | -- | 5,630,556.00 | -- | 2.84 | -- | 3.84 | 42.76 | 39.68 | 5.17 | 3.83 | -- | 559.36 | -- | -- | -7.21 | 8.33 | -34.77 | -- | -10.05 | -- |
| ZIM Laboratories Ltd | 3.55bn | 163.97m | 4.67bn | 525.00 | 28.50 | -- | 13.99 | 1.32 | 3.36 | 3.36 | 72.78 | -- | -- | -- | -- | 6,761,375.00 | -- | 3.96 | -- | 7.00 | 53.57 | 47.55 | 4.62 | 3.93 | -- | 4.08 | -- | 2.49 | 19.52 | 7.76 | 67.93 | 5.04 | 5.16 | -- |
| Wanbury Ltd | 5.69bn | 233.39m | 4.94bn | 1.58k | 21.18 | -- | 13.66 | 0.8675 | 7.12 | 7.12 | 173.80 | -- | -- | -- | -- | 3,598,099.00 | -- | 6.56 | -- | -- | 46.15 | 43.92 | 4.10 | 4.54 | -- | 1.82 | -- | -- | -2.26 | 5.95 | -112.76 | -- | 34.73 | -- |
| Medicamen Biotech Ltd | 1.71bn | 126.93m | 5.31bn | 388.00 | 42.72 | -- | 29.25 | 3.11 | 9.78 | 9.78 | 131.89 | -- | -- | -- | -- | 4,398,250.00 | -- | 7.17 | -- | 10.44 | 46.88 | 33.85 | 6.58 | 10.87 | -- | 4.76 | -- | 8.61 | 22.02 | 4.77 | -0.3555 | 7.98 | -4.21 | 0.00 |
| Kilitch Drugs (India) Ltd | 1.55bn | 145.71m | 5.62bn | 153.00 | 37.91 | -- | 34.83 | 3.62 | 9.21 | 9.21 | 98.24 | -- | -- | -- | -- | 10,132,730.00 | -- | 2.63 | -- | 3.59 | 39.68 | 33.85 | 8.25 | 5.01 | -- | 3.43 | -- | 2.93 | 22.20 | 22.30 | 41.82 | 15.19 | 1.79 | -- |
| Albert David Ltd | 3.55bn | 662.42m | 6.46bn | 1.27k | 9.75 | -- | 8.78 | 1.82 | 116.07 | 116.07 | 621.75 | -- | -- | -- | -- | 2,791,696.00 | -- | 7.61 | -- | 10.17 | 64.33 | 60.21 | 18.67 | 8.47 | -- | 108.22 | -- | 16.18 | 8.95 | 3.40 | 2.60 | 21.82 | 6.81 | 10.35 |
| Holder | Shares | % Held |
|---|---|---|
| Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 2024 | 71.00 | 0.00% |
